Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities
2 other identifiers
interventional
2,164
1 country
1
Brief Summary
Repeat testing for SARS-CoV-2 antibodies in disadvantaged communities will help identify active and recovered infections over time, and as more is understood about antibody protection, it may help identify persons who have immunity. Many questions about social barriers and behavioral facilitators remain unanswered. This project aims to evaluate the effectiveness of risk-based messaging and incentives that promote repeated testing for SARS-CoV-2 antibodies, as well as to understand social and behavioral determinants of COVID-19 testing and variations within sub-groups of this population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 29, 2021
CompletedFirst Posted
Study publicly available on registry
May 25, 2021
CompletedStudy Start
First participant enrolled
June 29, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 3, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 3, 2023
CompletedResults Posted
Study results publicly available
August 14, 2024
CompletedAugust 14, 2024
July 1, 2024
1.9 years
March 29, 2021
June 3, 2024
July 22, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Attendance Rate at Time 2 SARS-CoV-2 Antibody Test
Effectiveness of risk-based messaging and incentives to encourage attendance at Time 2 testing for SARS-CoV-2 antibodies
6 months
Secondary Outcomes (1)
Social and Behavioral Determinants of Antibody Testing
6 months
Study Arms (4)
Personal Risk + Loss Protection
EXPERIMENTALPersonal Risk + Loss Protection
Personal Risk + Lottery Incentive
EXPERIMENTALPersonal Risk + Lottery Incentive
Family Risk + Loss Protection
EXPERIMENTALFamily Risk + Loss Protection
Family Risk + Lottery Incentive
EXPERIMENTALFamily Risk + Lottery Incentive
Interventions
Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: "Antibody testing will help you understand your family's risk of getting COVID-19."
Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: "Antibody testing will help you understand your risk of getting COVID-19."
Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.
Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
Eligibility Criteria
You may qualify if:
- Adults and children 5 years of age and older
You may not qualify if:
- Children under 5 years of age
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Southern Californialead
- AltaMed Health Services Corporationcollaborator
- National Institute on Aging (NIA)collaborator
Study Sites (1)
AltaMed Health
Los Angeles, California, 90022, United States
Related Publications (1)
Doctor JN, Berg AH, Knight TK, Kadono M, Stewart E, Sonik R, Hochman M, Sood N. Cross-sectional study examining household factors associated with SARS-CoV-2 seropositivity in low-income children in Los Angeles. BMJ Open. 2023 May 31;13(5):e070291. doi: 10.1136/bmjopen-2022-070291.
PMID: 37258079DERIVED
Results Point of Contact
- Title
- Dr. Jason Doctor
- Organization
- University of Southern California
Study Officials
- PRINCIPAL INVESTIGATOR
Jason Doctor, PhD
University of Southern California
Publication Agreements
- PI is Sponsor Employee
- Yes
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 29, 2021
First Posted
May 25, 2021
Study Start
June 29, 2021
Primary Completion
June 3, 2023
Study Completion
June 3, 2023
Last Updated
August 14, 2024
Results First Posted
August 14, 2024
Record last verified: 2024-07